NEUROTHERA LABS INC
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
13.1M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Neurothera Labs Inc. operates a clinical-stage pharmaceutical company. The company engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. Neurothera Labs Inc. was formerly known as Miza III Ventures Inc. The company is based in Vancouver, Canada. As of February 23, 2023, Neurothera Labs Inc. operates as a subsidiary of SciSparc Ltd.
Financial Services
Shell Companies
TSXV
Key Financial Metrics
-
Revenue
-255,459
Net Income
C$-0.01
EPS (Diluted)
-140,772
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-255,396
Returns & Efficiency
Return on Assets (ROA)
-23.6%
Return on Equity (ROE)
-27.6%
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
1.1M
Total Debt
-
Debt to Equity
-
Current Ratio
6.93
Company Info
| Industry | Shell Companies |
| HQ | Vancouver, Canada |
| Currency | CAD |
| Website | wellution-hemp-gummies-united-states.jimdosite.com |
Peers
Royal Bank of Canada
RY.TO
310.1B
P/E: 15.2
214.0B
P/E: 10.4
Bank of Montreal
BMO.TO
131.5B
P/E: 15.5
120.4B
P/E: 13.6
Brookfield Corporation
BN.TO
118.4B
P/E: 79.9
The Bank of Nova Scotia
BNS.TO
116.7B
P/E: 14.0
96.5B
P/E: 28.1
76.9B
P/E: 15.0
Insider Activity
Sentiment
Bullish
Shares Bought
166,650
Shares Sold
0
Total Transactions
4
SEDAR+ Filings
View All Filings3
Annual Reports
13
Quarterly Reports
16
MD&A
16
News Releases
3
Material Changes
2
Prospectuses
5
Governance
39
Certifications
37
Other
●
2024-05-29
●
2023-05-31
●
2022-05-31
●
2025-10-29
●
2025-10-09
●
2021-07-19
●
2021-06-08
●
2021-04-15
●
2025-12-15
●
2024-08-21
●
2024-08-21
●
2022-07-27
●
2022-07-27
Interactive Charts
Company Profile
General Information
| Company Name | NEUROTHERA LABS INC |
| Ticker | NTLX.V |
| Exchange | TSXV |
| Sector | Financial Services |
| Industry | Shell Companies |
| Headquarters | Vancouver, Canada |
| Currency | CAD |
| Website | wellution-hemp-gummies-united-states.jimdosite.com |
Financial Summary
| Market Cap | 13.1M |
| Revenue | N/A |
| Net Income | -255,459 |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.01 |
| Net Margin | N/A |
| ROE | -27.6% |
| Dividend Yield | N/A |
Business Description
Neurothera Labs Inc. operates a clinical-stage pharmaceutical company. The company engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. Neurothera Labs Inc. was formerly known as Miza III Ventures Inc. The company is based in Vancouver, Canada. As of February 23, 2023, Neurothera Labs Inc. operates as a subsidiary of SciSparc Ltd.